Updated on 11 August 2026
7 Days Real-time Intelligent Aquaculture Disease Prediction
Founder and CEO at BWSea Technology
China (Hong Kong)
About
THE PROBLEM:
Disease is a major problem in aquaculture, causing up to 40% production loss and over-reliance on drugs and antibiotics, as existing approach to disease management is reactive based on diagnostic or symptoms detection only.
OUR SOLUTION:
Our Intelligent Disease Prediction solution, integrating AI and Biotech, transforms the reactive approaches to proactive prevention. It provides real-time disease risk forecast 7 days in advance for farmers to precisely prevent outbreak.
OUR IMPACT:
1. Improve aquatic animal food production by at least 10-20% through prevention of disease-caused mortality. Every 1% disease prevention leads to more than 2% profitability gain.
2. Improve sustainable production through reducing AMR and environmental impact by over-usage of drugs and antibiotics.
3. Improve income and livelihood of fish farmers in Asia first, then eventually 800+ million fish farmers globally by improving crop yield and profitability.
Project Location
- China (Hong Kong)
Project Website
https://www.bwsea.com/en/disease-prediction-system/
Project Format
- Private Project
Go Global Project
- Yes
ESG (Environmental, Social, and Governance)
- Yes
Project Stage
- Investment / Financing Discussion
Main Project Sector
- Agriculture, Food and Rural Development
Agriculture, Food and Rural Development
- Plantation, Fishery and Forestry
Technology
- Bio-Tech
- Environmental Technology
Total Project Value
- 1,000,001 to 2,500,000 USD
Investment Capital Required
- 1,000,001 to 2,500,000 USD
Interested Format of Cooperation
- Convertible Loan
- Direct Equity Investment
Preferred Financing Model
- Equity
- Open for negotiation
Type(s) of Last Financing Round of the project (if Applicable)
- Bootstrapping
Main Service(s) Required
- Environmental Services
- Information Technology Services
Information Technology Services
- Cloud Solution
- IoT
Organisation
China (Hong Kong)
Similar opportunities
Project
Novel MET Amplification-Targeting Small-Molecule Kinase Inhibitor (HJ-462 BIC)
- Yes
- Yes
- Debt
- Equity
- Bio-Tech
- Technology
- Joint Venture
- Private Project
- Health Technology
- Convertible Loan
- Equity (private)
- Financial Services
- Direct Equity Investment
- 5,000,001 to 7,500,000 USD
- 1,000,001 to 2,500,000 USD
- Investment / Financing Discussion
- M&A / Strategic Acquisition Opportunity
Haiyang Wang
CEO at Shanghai Haiju Biotechnology Co., Ltd.
China
Project
Paradigm-shifting healthtech solution dealing with the deadliest health condition worldwide
- Yes
- Yes
- Equity
- Bio-Tech
- Technology
- Private Project
- Convertible Loan
- Health Technology
- Medical Technology
- Financial Services
- Open for negotiation
- Professional Services
- Direct Equity Investment
- 2,500,001 to 5,000,000 USD
- 25,000,001 to 50,000,000 USD
- Public / Alternative Financing
- Investment / Financing Discussion
san pun
CEO at AiMorphous Healthtech
China (Hong Kong)
Project
AI-Enabled Quantitative MRI Platform for Early Disease Assessment
- No
- No
- Equity
- Technology
- Private Project
- Convertible Loan
- Equity (private)
- Financial Services
- Open for Negotiation
- Direct Equity Investment
- 1,000,001 to 2,500,000 USD
- 7,500,001 to 10,000,000 USD
- Investment / Financing Discussion
Carmen Ng
CEO at CAPRiser Group
Canada